Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Mar 6;189(9):E373.
doi: 10.1503/cmaj.732561.

Duloxetine: urinary incontinence and marketing authorization incontinence

Alain Braillon  1
Affiliations
Comment

Duloxetine: urinary incontinence and marketing authorization incontinence

Alain Braillon. CMAJ. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Maund E, Guski LS, Gøtzsche PC. Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. CMAJ 2017; 189: E194–203. - PMC - PubMed
    1. Wernicke J, Pangallo B, Wang F, et al. Hepatic effects of duloxetine-I: non-clinical and clinical trial data [published erratum in Curr Drug Saf 2009; 4:94]. Curr Drug Saf 2008;3:132–42. - PubMed
    1. Cymbalta (duloxetine hydrochloride). Silver Spring (MD): US Food and Drug Administration; 2011. Available: www.fda.gov/Safety/MedWatch/SafetyInformation/ucm255064.htm (accessed 2017 Jan. 27)
    1. Towards better patient care: drugs to avoid in 2016 [article in French]. Prescrire Int 2016;25: 105–11. - PubMed
    1. Hersh L, Salzman B. Clinical management of urinary incontinence in women [published erratum in Am Fam Physician 2013;88:427]. Am Fam Physician 2013;87:634–40. - PubMed

Substances